Revenues Working Against Adaptimmune Therapeutics Plc's (NASDAQ:ADAP) Share Price Following 27% Dive

Simply Wall St06:01 ET

Adaptimmune Therapeutics Plc's (NASDAQ:ADAP) Top Owners Are Retail Investors With 50% Stake, While 25% Is Held by Hedge Funds

Yahoo FinanceMar 4 05:39 ET

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

newsfileJan 30 16:00 ET

H.C. Wainwright Remains a Buy on Adaptimmune Therapeutics (ADAP)

TipRanksJan 22 09:55 ET · Ratings

Adaptimmune Therapeutics (NASDAQ:ADAP) Investors Are Sitting on a Loss of 86% If They Invested Five Years Ago

Yahoo FinanceJan 22 07:20 ET

Insider Sale: Chief Medical Officer of $ADAP (ADAP) Sells 5,584 Shares

Quiver QuantitativeJan 17 21:30 ET